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Background:  Susceptibility  testing  of herpes  simplex  virus  type 1  (HSV-1)  is  traditionally  performed  by  a
plaque  reduction  assay  (PRA),  but  this  is  labor  intensive,  time  consuming  and  has  a manual  read  out.
Objectives:  The  goal  of  this  study  was  to  develop  an  internally  controlled  real  time  PCR-based  phenotypical
susceptibility  test  for HSV-1  that  is  suitable  for use in a  clinical  diagnostic  setting.
Study  design:  A  DNA  reduction  assay  (DRA)  was  developed  and  validated  on  a  test panel  of  26  well-
characterized  isolates  of  varying  susceptibility  to aciclovir  or foscarnet,  including  low-level  resistant
isolates.  The  DRA consisted  of  pre-culture  of  a clinical  sample  for  48  h  and  subsequent  culture  in the
presence  of  antivirals  for  24  h.  Viral  DNA  concentration  in  the  culture  lysates  was  measured  by  an  inter-
nally  controlled  quantitative  real-time  HSV-1  PCR and  corrected  for  cell  count  and  lysis  by  beta-globineal time PCR PCR.  DRA  results  were  compared  to results  from  PRA  and  sequence  analysis.
Results:  DRA  results  were  in  accordance  with  PRA  results  for both  aciclovir  and  foscarnet  susceptibility
and  appeared  to have  good  discriminative  value  for low-level  resistance  due  to  UL30  gene  mutations.
Although  the  direct  application  of  DRA  in  clinical  samples  appeared  not  possible,  short  pre-culture  of
sure
curat48  h was  sufﬁcient  and  en
Conclusions:  DRA  is  an  ac
. Background
Severe and persistent infections with herpes simplex virus
ype 1 (HSV-1) are common in immunocompromised patients,
specially patients receiving chemotherapy and hematopoietic
tem cell transplants, and are frequently associated with antiviral
esistance.1 The fastest approach to HSV-1 susceptibility testing
s sequence analysis of the UL23 gene of the HSV-1 thymidine
inase that catalyzes a necessary phosphorylation step of aciclovir
r of the UL30 gene of the HSV-1 DNA polymerase. Sequencing of
hese genes may  reveal a resistance conferring mutation, but since
ucleotide variations are common, mutations of unknown signif-
cance are also found frequently.1–4 In such cases, phenotypical
usceptibility testing of HSV-1 is still required which is tradition-
lly performed by a plaque reduction assay (PRA).5 PRA requires
Abbreviations: ACV, aciclovir; d, days; del, deletion; DRA, DNA reduction assay;
OS, foscarnet; fs, frameshift; GCV, ganciclovir; HSV-1, herpes simplex virus type
;  ins, insertion; n.d., not determined; PhHV, Phocid Herpes Virus; PRA, plaque
eduction assay; R, resistant; S, susceptible; SCT, stem cell transplantation; sub,
ubstitution; vACV, valaciclovir.
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4-P, Leiden University Medical Center, P.O. Box 9600, NL-2300 RC Leiden, The
etherlands. Tel.: +31 71 5263931; fax: +31 71 5266761.
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Open access under the Elsevier OA license.d  results  within  a clinically  relevant  time  frame  of 5 days.
e,  rapid  and  easy  to perform  phenotypical  susceptibility  test  for  HSV-1.
© 2012 Elsevier B.V. 
viral titration and prolonged incubation until viral cytopathogenic
effect (CPE) is visible and is labor intensive, subjective and time
consuming.
Faster phenotypical assays using more sensitive and objective
endpoints are preferable. Real time PCR has previously been applied
successfully to measure viral concentrations in HSV-1 phenotypi-
cal susceptibility tests.6,7 Stranska et al.6 measured inhibition of
viral DNA replication by antivirals in culture supernatant, which
may  be less indicative of intracellular viral replication. The proto-
col described by Thi et al.7 measured viral DNA in cells but used
crude cell lysate in an uncontrolled PCR.
2. Objectives
The goal of this study was to design, optimize and validate a
rapid internally controlled real time PCR-based phenotypical sus-
ceptibility test for HSV-1 for routine use in a clinical diagnostic
setting.
3. Study design
Open access under the Elsevier OA license.3.1. Viral isolates and clinical samples
For DNA reduction assay (DRA) validation using viral isolates
(Table 1), susceptible reference strain HSV F (ATCC number VR-733,
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Table 1
Features of previously characterized HSV-1 isolates used for DNA reduction assay validation.
Patient/source Isolate Clinical and treatment details UL23 mutation UL30 mutation
ATCC HSV F Susceptible reference strain None None
A #1 SCT, mucositis, pre-treatment None None
#11 Mucositis, ACV iv 13 days delG180 → fs61 None
#12  Ulcerative esophagitis, ACV iv 13 days and vACV 4 days delG180 → fs61 None
#13 Ulcerative esophagitis, ACV iv 22 days and vACV 9 days delG180 → fs61 None
B  #2 SCT, lip lesion, pre-treatment None None
#21  Severe facial and days oral lesions, ACV iv 52 days and
vACV 32 days
G488A → subR163H None
#24 Lip  lesion, ACV iv 44 days None G2171A → subS724N
C  #3 SCT, mucositis, pre-treatment None None
#22 Persistent mucositis, ACV iv 13 days C566T → subA189V None
D  #4 SCT, mucositis, pre-treatment None None
#14  Persistent mucositis, ACV iv 5 days and GCV iv 12 days insG430 → fs146 None
E  #5 SCT, mucositis, pre-treatment None None
#23 Persistent mucositis, vACV 8 days and ACV iv 7 days insG430 → fs146 None
F #10  SCT, encephalitis, ACV iv 15 days T1033C → subS345P G1684A → subA562T
G  #20 SCT, persistent mucositis, ACV iv 26 days A314C → subH105P None
H #7 SCT, stomatitis, pre-treatment None None
#8 Persistent stomatitis, ACV iv 5 days None None
#15 Persistent stomatitis, ACV iv 12 days insG430 → fs146 None
I  #16 SCT, treatment unknown delG430 → fs146 None
J  #18 SCT, treatment unknown insC548 → fs185 None
K  #19 SCT, treatment unknown C310T → stop104 None
L  #25 SCT, treatment unknown None C2156T → subA719V
M #6 Chemotherapy, mucositis, vACV 5 days None None
#17 Persistent mucositis, vACV 12 days and ACV iv 10 days delC460 → fs155 None
N #9  Immunocompetent, recurrent genital HSV-1 despite
vACV prophylaxis
None G1947T → subE649D
All samples were isolated from swab samples from mucous membranes or skin, except for sample 10 which was isolated from cerebrospinal ﬂuid. Patient B,10 patients I–L8
and patients A, C, D and H9 were described in previous studies.
ACV, aciclovir.
d, days.
del, deletion.
fs, frameshift.
GCV, ganciclovir.
ins, insertion.
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anassas, VA, USA), and 25 previously characterized viral isolates
rom 14 patients that were clinically suspected of having a resis-
ant virus and that had been sent for susceptibility testing to an
xternal laboratory or that were described in previous studies were
sed.8–10 The test panel included pre-treatment viral isolates if
vailable. Aliquots of viral isolates were stored at −80 ◦C. For DRA
alidation directly on clinical samples (swabs), the clinical samples
rom which isolates #5 and #17 had been cultured and 7 randomly
elected HSV-1 positive clinical samples were used.
.2. UL23 and UL30 gene sequence analysis
Genotypical resistance analysis was performed by cycle
equencing after PCR ampliﬁcation on an ABI Prism 3100 Genetic
nalyzer (Applied Biosystems). Ampliﬁcation and sequencing
rimers and PCR conditions are shown in Table 2. UL23 ampli-
cation was performed in 50 l containing 25 l HotStart Taq
astermix (Qiagen, Hilden, Germany) and 15 pmol of each primer.
or UL30 ampliﬁcation, nested PCR was necessary for clinical sam-
les, but not for viral isolates. PCR and nested PCR were performed
n 50 l containing 1 l Advantage®-GC 2 Polymerase mix  (Clon-
ech, Westburg, Leusden, The Netherlands), 10 l Advantage®-GC
 PCR Buffer, 25 mol  GC-melt, 0.2 mM dNTP mix  and 15 pmol
f each primer. All cycle sequencing reactions were performed in
0 l containing 2 l Big Dye Terminator v1.1 (Applied Biosystems,
arlsbad, CA, USA), 6 l sequencing buffer and 8 pmol primer. The
etection limit of the assay was around 1000 copies/ml for the UL23
ene and around 5000 copies/ml for the UL30 gene. Sequences werecompared to pre-treatment isolates if available and to the sequence
of HSV F.
3.3. Plaque reduction assay
The protocol M33-A Antiviral Susceptibility Testing: Herpes Sim-
plex Virus by Plaque Reduction Assay of the Clinical and Laboratory
Standards Institute5 using Vero cells was modiﬁed by including
the use of microcrystalline cellulose (Avicel® RC/CL, FMC  BioPoly-
mer, Philadelphia, USA) as overlay.11 For viral titration, the overlay
consisted of 1.5 ml  of 0.6% Avicel® RC/CL in sterile water mixed 1:1
with 2× EMEM without phenol red (Gibco) with 4% FCS and 4 mM
glutamine. After incubation, cells were ﬁxed with formalin and,
after aspiration of the overlay, stained with crystal violet. For PRA,
the overlay consisted of twofold serial dilutions of aciclovir (acy-
cloguanosine, Sigma–Aldrich, Schnelldorf, Germany) or foscarnet
(sodium phosphonoformate tribasic hexahydrate, Sigma–Aldrich)
in 2× EMEM without phenol red with 4% FCS and 4 mM glutamine
mixed 1:1 with 0.6% Avicel® RC/CL in sterile water. The aciclovir
concentration range was 0.12–16 mg/L and for foscarnet the con-
centration range was  16.7–400 mg/L. Isolates having an IC50 value
≥2 mg/L for aciclovir or ≥100 mg/L for foscarnet were considered
resistant.53.4. Real time PCR based phenotypical susceptibility test
DRA was  performed on supernatants from either HSV-1 culture
isolates (Table 1) or directly on positive clinical samples inoculated
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Table 2
Primers, probes and PCR conditions used for UL23 and UL30 gene sequence analysis and DNA reduction assay.
Target Orientation Sequence (5′ → 3′) Positiona Amplicon
size (bp)
PCR protocol
UL23 gene HSV-1 ampliﬁcation
Sense TCCACTTCGCATATTAAGGT −146 1335 15 min  95 ◦C 40×: 1 min 95 ◦C 1 min
50 ◦C 1 min  72 ◦C 1×: 10 min 72 ◦CAntisense CTGTCTTTTTATTGCCGTCA +38
UL23  gene HSV-1 sequencing
Sense GCTTAACAGCGTCAACAGC −84
1 min  96 ◦C 25×: 10 s 96 ◦C 5 s 50 ◦C
4 min  60 ◦C
Sense AGACAATCGCGAACATCTAC 284
Antisense CCGATATCTCACCCTGGTC 321
Sense ATACGGTGCGGTATCTGC 731
Antisense AAAGCTGTCCCCAATCCT 770
Antisense TGTCTTTTTATTGCCGTCAT +37
UL30  gene HSV-1 ampliﬁcation
Sense GAGGACGAGCTGGCCTTTCCG 1126 1810 3 min  94 ◦C 40×:  30 s 94 ◦C 30 s
60 ◦C 2 min  68 ◦C 1×: 3 min 68 ◦CAntisense AAAACAGCAGGTCGACCAGGGC 2914
UL30  gene HSV-1 nested
ampliﬁcation
Sense GACCTCCCCGAATCCCA 1252 1652 3 min  94 ◦C 30×:  30 s 94 ◦C 30 s
60 ◦C 2 min  68 ◦C 1×: 3 min 68 ◦CAntisense CGGTTGATAAACGCGCAGTTG 2883
UL30  gene HSV-1 sequencing
Sense GAGGACGAGCTGGCCTTT 1126
1 min  96 ◦C 25×: 10 s 96 ◦C 5 s 50 ◦C
4 min  60 ◦C
Sense GAGTACTGCATACAGGATTC 1726
Antisense TGGCCGTCGTAGATGGTG 1833
Antisense TGCTGCACTCCCGTGAAC 2457
Antisense AAAACAGCAGGTCGACCAG 3708
Senseb GACCTCCCCGAATCCCA 1252
Antisenseb CGGTTGATAAACGCGCAGTTG 2883
Glycoprotein B gene HSV-1
ampliﬁcation
Sense TCAAGACCACCTCCTCCATC 1484–1503 130
15 min  94 ◦C 50×:  30 s 94 ◦C 30 s
55 ◦C 30 s 72 ◦C
Antisense AGGGTCAGCTCGTGATTCTG 1594–1613
Probe  FAM AACATATCGTTGACATGG BHQ-1 1545–1562
Glycoprotein B gene PhHV-1
ampliﬁcation
Sense GGGCGAATCACAGATTGAATC 159–179 89
15 min  94 ◦C 50×:  30 s 94 ◦C 30 s
55 ◦C 30 s 72 ◦C
Antisense GCGGTTCCAAACGTACCAA 229–247
Probe Cy5 TTTTTATGTGTCCGCCACCATCTGGATC BHQ-2 197–224
-Hemoglobin gene
Sense AAGTGCTCGGTGCCTTTAGTG 200–220 97
15 min  94 ◦C 50×:  30 s 94 ◦C 30 s
55 ◦C 30 s 72 ◦C
Antisense ACGTGCAGCTTGTCACAGTG 222–245
Probe YAK TGGCCTGGCTCACCTGGACAACCT BHQ-1 277–296
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aa From startcodon in gene in sense orientation.
b In case of nested ampliﬁcation.
nto A549 cells and incubated for 48 h. Supernatants from pre-
ultured clinical samples were diluted 1:100 in EMEM regardless
f viral titers whereas stored viral isolates were diluted to obtain
iral loads between 104 and 107 copies/ml. A conﬂuent monolayer
f Vero cells was cultured in 24 wells plates. Subsequently 300 l
f the diluted sample was added to each well after removal of
ulture medium. After 1 h of incubation at 37 ◦C in a humidiﬁed
tmosphere of 5% CO2 the inoculum was removed and replaced
y 1 ml  of aciclovir or foscarnet in EMEM with 5% FCS. The con-
entration range of the serial dilutions (6 dilutions per isolate)
f aciclovir was 0.12–16 mg/L and for foscarnet 8.35–100 mg/L.
ll samples were assayed in quadruplicate and incubated
or 24 h.
Then, after removal of the culture medium, 200 l of AL Lysis
uffer (QIAamp® DNA Mini and Bloodkit, Qiagen) spiked with
hocid Herpes Virus (PhHV, kindly provided by Dr. M. Schutten,
rasmus Medical Center, Rotterdam, The Netherlands) was added
o the monolayer and incubated for 15 min  at room temperature.
ysate was harvested and all wells were rinsed with 200 l PBS
o include any remaining viral DNA which was then added to the
ysate. After addition of 20 l Proteinase K (Qiagen), samples were
ncubated for 10 min  at 56 ◦C and 10 min  at 95 ◦C. Samples were
ixed with 200 l ethanol 100% and transferred to a QIAamp® mini
pin column (Qiagen) and centrifuged for 1 min  at 6000 × g. Wash-
ng steps were omitted to limit hands on time. DNA was  eluted in
00 l AE buffer (Qiagen) by centrifugation for 1 min  at 6000 × g.
 real time PCR for beta-globin and a multiplex real time PCR for
hHV and HSV-1 were performed on a CFX96 real-time detection
ystem (Bio-Rad, Veenendaal, The Netherlands). Primers, probes
nd PCR conditions are shown in Table 2. PCRs were carried out
n 50 l volume containing 25 l HotStart Taq mastermix (Qiagen)
nd 4 mM MgCl2 (5 mM for beta-globin).For quantitation, a standard of HSV-1 (cultured ﬁeld isolate or
ATCC KOS strain VR-1493D) was calibrated using a quantitated DNA
control of the HSV-1 MacIntyre strain (Advanced Biotechnologies
Inc., Columbia, MD). PhHV served as an internal control for DNA
extraction and PCR inhibition12 and those wells that were out-
liers in the PhHV PCR (more than 3 CT-values different from assay
average) were considered inhibited and were excluded from the
analysis. The beta-globin PCR was  performed as a control for cell
concentration and cell lysis for which the same exclusion crite-
ria were used. The concentration of antiviral agents to inhibit viral
DNA replication by 50% (IC50) was  calculated after plotting the viral
concentration versus the concentration of antiviral agent. Provi-
sional resistance breakpoints were adapted from Thi et al.7 and set
at ≥0.23 mg/L for aciclovir and at ≥13 mg/L for foscarnet.
4. Results
4.1. Viral isolates
PRA and sequence analysis of the UL23 and UL30 genes were
repeated on aliquots of the viral isolates to be used for DRA. PRA
results for aciclovir were concordant with genotypic analysis in 25
isolates including 11 with no mutations in either the UL23 or UL30
genes, 13 with a mutation in UL23, and 1 with a mutation in UL30.
One isolate (#25) had a UL30 mutation but was susceptible to aci-
clovir by PRA but with an elevated IC50 of 1.03 mg/L (Table 3). PRA
results for foscarnet were concordant in 23 isolates, including 10
with no mutations and 13 with a mutation in UL23, failed in one
isolate (#2) and were discordant with genotypical analysis in the
two isolates with UL30 mutations (#24 and #25, Table 3). Both iso-
lates #24 and #25 showed diminished susceptibility to foscarnet
22 M.T. van der Beek et al. / Journal of Clinical Virology 56 (2013) 19– 24
Table 3
UL23 and UL30 sequence analysis, plaque reduction assay and DNA reduction assay results on HSV-1 isolates.
Isolate Resistance-associated mutation PRA DRA
IC50 ACV (mg/L) IC50 FOS (mg/L) Conclusion IC50 ACV (mg/L) IC50 FOS (mg/L) Conclusion
HSV-F None 0.08 21.9 ACV S FOS S 0.10 8.75 ACV S FOS S
#1  None 0.10 21.3 ACV S FOS S 0.08 n.d. ACV S FOS n.d.
#2  None 0.45 Failed ACV S FOS n.d. 0.06 n.d. ACV S FOS n.d.
#3 None 0.16 18.2 ACV S FOS S 0.12 n.d. ACV S FOS n.d.
#4 None 0.09 26.0 ACV S FOS S 0.07 n.d. ACV S FOS n.d.
#5  None 0.15 19.4 ACV S FOS S 0.07 n.d. ACV S FOS n.d.
#6  None 0.23 16.7 ACV S FOS S 0.12 n.d. ACV S FOS n.d.
#7  None 0.28 11.4 ACV S FOS S 0.08 n.d. ACV S FOS n.d.
#8  None 0.28 17.8 ACV S FOS S 0.18 n.d. ACV S FOS n.d.
#9 None 0.06 10.5 ACV S FOS S Failed Failed Failed
#10 None 0.11 35.7 ACV S FOS S 0.08 12.81 ACV S FOS S
#11  UL23 16.21 11.3 ACV R FOS S 2.65 n.d. ACV R FOS n.d.
#12 UL23 15.16 16.3 ACV R FOS S 3.67 n.d. ACV R FOS n.d.
#13  UL23 11.20 10.1 ACV R FOS S 0.76 n.d. ACV R FOS n.d.
#14  UL23 11.82 12.5 ACV R FOS S 6.17 n.d. ACV R FOS n.d.
#15  UL23 15.56 9.1 ACV R FOS S 2.40 n.d. ACV R FOS n.d.
#16  UL23 13.92 25.0 ACV R FOS S 3.18 5.98 ACV R FOS S
#17  UL23 16.70 17.4 ACV R FOS S 3.06 n.d. ACV R FOS n.d.
#18 UL23 37.95  25.0 ACV R FOS S 4.62 4.81 ACV R FOS S
#19  UL23 6.88 25.0 ACV R FOS S 2.42 9.11 ACV R FOS S
#20 UL23 10.55 15.5 ACV R FOS S 1.63 n.d. ACV R FOS n.d.
#21  UL23 6.15 21.6 ACV R FOS S 4.69 n.d. ACV R FOS n.d.
#22  UL23 6.33 5.8 ACV R FOS S 0.67 n.d. ACV R FOS n.d.
#23  UL23 14.25 11.7 ACV R FOS S 0.95 5.63 ACV R FOS S
#24  UL30 5.81 88.7 ACV R FOS S 0.64 22.13 ACV R FOS R
#25 UL30 1.03 43.4 ACV S FOS S 0.99 29.73 ACV R FOS R
IC50 values greater than or equal to resistance breakpoint (see text) in bold.
ACV, aciclovir.
DRA, DNA reduction assay.
FOS, foscarnet.
n.d., not determined.
PRA, plaque reduction assay.
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lthough not meeting the proposed resistance criteria according to
LSI.
DRA was validated for aciclovir on all isolates and for foscarnet
n UL30 mutants and in a subset of UL23 mutants. DRA failed in one
solate (#9). DRA results (Table 3) for aciclovir were in concordance
ith genotyping of all 25 isolates using the provisional breakpoint
f 0.23 mg/L, but not in concordance with PRA for 1 isolate (#25). By
RA, IC50 values of all 15 UL23 and UL30 mutants, including isolate
25, were at least at least 2.8-fold the tentative breakpoint and 6.4-
old the IC50 value of the susceptible reference isolate. DRA results
Table 3) for foscarnet were concordant with genotypical results
n the 8 tested isolates, but were not concordant with PRA in two
solates (#24 and #24). These UL30 mutants had IC50-values that
ere at least 1.7-fold the tentative breakpoint and at least 2.5-fold
he IC50 value of the susceptible reference isolate.
.2. Clinical samples
DRA was applied to 9 clinical samples (Table 4) and demon-
trated aciclovir resistance in two UL23 mutants (Table 4) and failed
n one of the clinical samples that had a relatively low viral load after
8 h of pre-culture (7.9 × 104 copies/ml).
. Discussion
This study optimized and validated a protocol for phenotypical
usceptibility testing of HSV-1. A fast and easily applicable pro-
ocol was developed that compared very well to results obtained
y genotypical tests and by PRA. Although only tentative break-
oints exist for susceptibility testing of HSV-1 using a real time-PCR
ased approach, classiﬁcation of the DRA results according to thetentative breakpoints adopted from Thi et al.7 resulted in very high
concordance. DRA failed in only one isolate.
DRA provided results within ﬁve days after sampling (Fig. 1).
No visible viral CPE is required when viral replication is measured
by sensitive methods such as real time PCR and hence incubation
time can be reduced compared to PRA. Pilot experiments using both
susceptible and resistant isolates showed comparable IC50 values
over broad ranges of viral inoculum, given sufﬁcient viral input
(10,000 copies/ml), hence allowing a ﬁxed dilution of pre-cultured
clinical samples without the need for viral titration. Hands on time
could be reduced by the use of a simpliﬁed DNA isolation procedure.
DRA was  applicable to all clinical samples with a viral load of at
least 10,000 copies/ml. In the ﬁnal format of quadruplicate testing
the coefﬁcient of variation of the log-transformed viral concentra-
tions was 5% on average. On average 0.3 wells were excluded per
24-well assay because of PCR inhibition and 1.2 wells because of
insufﬁcient beta-globin concentration.
As shown in previous studies,1–3 mutations of unknown sig-
niﬁcance are commonly found in HSV-1 clinical isolates and
a pre-treatment sample for comparison of mutations is often
not available. Three isolates contained UL30 mutation Asp-
672 → Asn which has recently been described both as a natural
polymorphism2 and as an aciclovir and foscarnet resistance-
associated mutation.13 Phenotypical susceptibility tests showed
aciclovir and foscarnet susceptibility in an isolate with no other
resistance-associated mutations making Asp-672 → Asn unlikely
as a resistance-associated mutation. This nicely demonstrates the
usefulness of phenotypical susceptibility testing.
Low level resistance to aciclovir and foscarnet due to muta-
tions in the UL30 gene is possibly more accurately detected by
DRA than by PRA. Both our PRA and PRA performed initially (by
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Table 4
UL23 sequence analysis and DNA reduction assay results performed directly on HSV-1 positive clinical samples.
Patient/source Clinical and treatment details Viral load (10log copies/ml) Resistance associated
UL23 gene mutations
IC50 ACV in
DRA (mg/L)
In sample After
pre-culture
At input
in DRA
At read-out
of DRA
In sample After
pre-culture
After
pre-culture
Eb SCT, mucositis. pretreatment 7.4 8.4 4.9 7.2 None None 0.07
Ma Chemotherapy, persistent
mucositis. vACV 12 days and
ACV iv 10 days
5.3 7.3 5.4 6.6 delC460 → fs155 delC460 → fs155 3.06
O  SCT, HSV mouth. no antivirals 4.1 5.9 3.9 5.9 None None 0.06
P  Chemotherapy, HSV lip, no
antivirals
5.3 7.1 5.1 6.1 None None 0.16
Q Infant, eczema herpeticum.
treatment unknown
5.4 4.9 2.9 3.9 None None Failedc
R SCT, HSV mouth. no antivirals 6.4 7.1 5.1 7.5 None None 0.06
S  Unknown 6.9 6.5 4.5 6.1 None None 0.06
T  SCT, HSV mouth. ACV iv 17
days
6.9 6.6 4.6 6.5 insG430 → fs146 insG430 → fs146 5.74
U  Infant, eczema herpeticum.
treatment unknown
8.3 6.2 4.2 6.6 None None 0.06
IC50 values greater than or equal to resistance breakpoint (see text) in bold.
a See Table 1, isolate #17.
b See Table 1 isolate #5.
c IC50 value 0.06 mg/L at 1:10 dilution.
ACV, aciclovir.
d, days.
del, deletion.
DRA, DNA reduction assay.
fs, frameshift.
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CT, stem cell transplantation.
ACV, valaciclovir.
thers) showed a level of resistance around or below the speciﬁed
reakpoint, as previously described for UL30 mutations A719V and
724N.8,10,14,15 This may  be due to the speciﬁc UL30 gene muta-
ions or because low-level resistance or intermediate susceptibility
ig. 1. Time frame (working days) of susceptibility testing by DNA reduction assay.may  not be accurately deﬁned by the CLSI breakpoints.5 Nev-
ertheless, DRA consistently showed increased IC50 values above
the tentative breakpoints in these isolates. Because knowledge on
the clinical signiﬁcance of such mutations is lacking, it would be
interesting to study how infections with such isolates should be
treated.
Some limitations apply to the DRA. Firstly, without a short pre-
culture, no viral replication was  observed in DRA, but our protocol
was suitable for clinical samples after a ﬁxed short term pre-culture.
This may  be due to the low inoculum present in clinical sam-
ples, although pre-culture did not increase viral loads very much.
It can also be related to the short duration of incubation of the
DRA, although prolonging the assay to 48 h did not solve the prob-
lem. Possibly, adaptation of virus to cell culture is necessary for
a successful DRA. To study the possible selection pressure during
pre-culture of a clinical sample, nine clinical samples were cultured
for 48 h. The nucleotide sequence of the entire UL23 gene was com-
pared between the clinical samples and the viral isolates after 48 h
of pre-culture (Table 4) and no differences were found.
Secondly, the detection limit of DRA precluded its use for weakly
positive samples. This limitation may  be partly overcome by adap-
tation of the dilution in samples with a lower viral load, which was
applied successfully in one of our clinical samples in which a 1:10
diluted culture supernatant was  used instead of 1:100 (Table 4).
Finally, the assay was  validated for HSV-1 only.
In clinical diagnostics, a genotypical approach has the advan-
tages of speed and technical ease. A two-step approach may
therefore be practical in this setting, starting with UL23 and UL30
gene sequencing of, preferably, a pre- and on-treatment sam-
ple and subsequent phenotypical conﬁrmation of resistance if
mutations of unclear signiﬁcance are encountered. A multicen-
ter trial evaluating assay applicability and reproducibility and the
clinical outcome in relation to the tentative breakpoints, should
conﬁrm the role of DRA in phenotypical susceptibility testing of
HSV-1.
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